Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
CAPS Rating:
A biopharmaceutical company that acquires and advances a diversified portfolio of drug candidates, with a focus on oncology, urology and other critical health challenges for which there are few other treatment options.
RSS Headlines
Fool UK
Recs
Appears undervalued based on drugs approved in the pipeline. Also is a potential take over cadidiate